Matinas BioPharma Holdings, Inc. financial data

Symbol
MTNB on NYSE
Location
Bedminster, NJ
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 347% % -40%
Debt-to-equity 64% % 108%
Return On Equity -241% % -96%
Return On Assets -147% % -56%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6,406,191 shares 26%
Common Stock, Shares, Outstanding 5,901,091 shares 16%
Entity Public Float $38,700,000 USD -49%
Common Stock, Value, Issued $1,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 5,435,829 shares 7.9%
Weighted Average Number of Shares Outstanding, Diluted 5,435,829 shares 7.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $8,072,000 USD -42%
General and Administrative Expense $6,938,000 USD -25%
Costs and Expenses $13,831,000 USD -37%
Operating Income (Loss) $13,831,000 USD 37%
Net Income (Loss) Attributable to Parent $16,866,000 USD 20%
Earnings Per Share, Basic -3 USD/shares 53%
Earnings Per Share, Diluted -3 USD/shares 53%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $5,435,000 USD -47%
Marketable Securities, Current $500,000 USD -96%
Assets, Current $5,653,000 USD -52%
Property, Plant and Equipment, Net $156,000 USD -91%
Operating Lease, Right-of-Use Asset $1,351,000 USD -48%
Intangible Assets, Net (Excluding Goodwill) $2,260,000 USD -25%
Goodwill $1,336,000 USD 0%
Assets $9,695,000 USD -53%
Accounts Payable, Current $80,000 USD -77%
Accrued Liabilities, Current $564,000 USD -46%
Liabilities, Current $1,495,000 USD -30%
Deferred Income Tax Liabilities, Net $257,000 USD -25%
Operating Lease, Liability, Noncurrent $1,472,000 USD -37%
Liabilities $3,235,000 USD -33%
Accumulated Other Comprehensive Income (Loss), Net of Tax $51,000 USD 90%
Retained Earnings (Accumulated Deficit) $208,875,000 USD -9.1%
Stockholders' Equity Attributable to Parent $6,460,000 USD -59%
Liabilities and Equity $9,695,000 USD -53%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,007,000 USD 65%
Net Cash Provided by (Used in) Financing Activities $1,647,000 USD 3008%
Net Cash Provided by (Used in) Investing Activities $2,000,000 USD -33%
Common Stock, Shares Authorized 500,000,000 shares 100%
Common Stock, Shares, Issued 5,901,091 shares 16%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $360,000 USD 90%
Deferred Tax Assets, Valuation Allowance $46,248,000 USD 13%
Deferred Tax Assets, Gross $45,991,000 USD 14%
Operating Lease, Liability $2,318,000 USD -24%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $16,866,000 USD 19%
Lessee, Operating Lease, Liability, to be Paid $2,650,000 USD -27%
Property, Plant and Equipment, Gross $218,000 USD -94%
Operating Lease, Liability, Current $846,000 USD 15%
Lessee, Operating Lease, Liability, to be Paid, Year Two $944,000 USD -9.2%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,040,000 USD 4.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $332,000 USD -43%
Lessee, Operating Lease, Liability, to be Paid, Year Three $273,000 USD -71%
Deferred Tax Assets, Operating Loss Carryforwards $28,270,000 USD 12%
Preferred Stock, Shares Authorized 10,000,000 shares
Lessee, Operating Lease, Liability, to be Paid, Year Four $138,000 USD -49%
Additional Paid in Capital $214,399,000 USD 4%
Depreciation, Depletion and Amortization $18,000 USD -81%